Published : 12/09/2020 - Categories : News
Alsachim has synthesized a full set of labeled and unlabeled Tyrosine Kinase Inhibitors standards.
During the last decades, targeted therapy has been introduced as an alternative treatment in Oncology. It is directed against cancer-specific molecules and signaling pathways allowing a more limited nonspecific toxicities.
Tyrosine Kinases are an especially important target, it promotes phosphorylation which can affect normal cellular functions such as apoptosis, proliferation and differentiation.
Alsachim supports new research developments through a continuous release of new standards.
Contact us now to get more information and a personalized quote for these products.
Share this news
Search on news
- 2023 (4)
- 2022 (4)
- 2021 (4)
- 2020 (11)
- 2019 (4)
- 2018 (1)
- 2017 (1)